03/06/2025
6:02 AM | ESSA Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/14/2025
9:26 AM | BML Investment Partners, L.P. (Filed by)
ESSA Pharma (Subject)
| Form SCHEDULE 13G/A | |
02/14/2025
8:49 AM | BML Investment Partners, L.P. (Filed by)
ESSA Pharma (Subject)
| Form SCHEDULE 13G/A | |
02/14/2025
8:00 AM | ESSA Pharma (Subject)
RTW INVESTMENTS, LP (Filed by)
| Form SCHEDULE 13G/A | |
02/11/2025
6:00 AM | ESSA Pharma (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
02/11/2025
6:02 AM | ESSA Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/17/2024
6:00 AM | ESSA Pharma (Filer)
| Form 10-K
Annual report pursuant to Section 13 or 15(d) | |
12/17/2024
6:02 AM | ESSA Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/13/2024
8:32 PM | ESSA Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/06/2024
6:00 AM | ESSA Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/14/2024
6:32 PM | BB BIOTECH AG (Filed by)
ESSA Pharma (Subject)
| Form SC 13G/A | |
Get the Latest News and Ratings for EPIX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for ESSA Pharma and its competitors with MarketBeat's FREE daily newsletter. |
11/14/2024
5:56 AM | ESSA Pharma (Subject)
RTW INVESTMENTS, LP (Filed by)
| Form SC 13G/A | |
11/08/2024
3:56 PM | ESSA Pharma (Subject)
TANG CAPITAL MANAGEMENT LLC (Filed by)
| Form SC 13D | |
11/07/2024
11:50 AM | BML Investment Partners, L.P. (Filed by)
ESSA Pharma (Subject)
| Form SC 13G | |
11/05/2024
11:06 AM | BB BIOTECH AG (Reporting)
BIOTECH GROWTH N V (Reporting)
ESSA Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/01/2024
3:30 PM | ESSA Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/07/2024
2:00 PM | ESSA Pharma (Issuer)
Virsik Peter (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/09/2024
1:03 PM | ESSA Pharma (Issuer)
Virsik Peter (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/03/2024
5:57 PM | ESSA Pharma (Issuer)
Virsik Peter (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/05/2024
6:00 AM | ESSA Pharma (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
08/05/2024
6:01 AM | ESSA Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/14/2024
6:00 AM | ESSA Pharma (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
05/14/2024
6:01 AM | ESSA Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/06/2024
4:17 PM | ESSA Pharma (Issuer)
Virsik Peter (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/25/2024
9:35 AM | ESSA Pharma (Issuer)
Glickman Richard M (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/05/2024
5:16 PM | ESSA Pharma (Issuer)
Virsik Peter (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/05/2024
2:02 PM | ESSA Pharma (Subject)
Virsik Peter (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
